Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer

详细信息    查看全文

• 作者：Yu-Wen He ; Mei-Ling Zhao ; Xin-Yun Yang ; Jun Zeng…
• 关键词：Non ; small cell lung cancer ; Excision repair cross ; complementation group 1 ; Ribonucleotide reductase M1 ; Thymidylate synthase ; Chemotherapy
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：75
• 期：4
• 页码：861-867
• 全文大小：588 KB
• 参考文献：1. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D (2011) Global cancer statistics. CA Cancer J Clin 61: pp. 69-90 CrossRef
  2. McCloskey, P, Balduyck, B, Schil, PE, Faivre-Finn, C, O’Brien, M (2013) Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer 49: pp. 1555-1564 CrossRef
  3. Arriagada, R, Bergman, B, Dunant, A, Le Chevalier, T, Pignon, JP, Vansteenkiste, J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: pp. 351-360 CrossRef
  4. Geiger, S, Schlemmer, M, Heinemann, V, Stemmler, HJ (2010) Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. Anticancer Drugs 21: pp. 799-804 CrossRef
  5. Arriagada, R, Dunant, A, Pignon, JP, Bergman, B, Chabowski, M, Grunenwald, D, Kozlowski, M, Pechoux, C, Pirker, R, Pinel, MI, Tarayre, M, Chevalier, T (2010) Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28: pp. 35-42 CrossRef
  6. Filipits, M, Pirker, R (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74: pp. 355-363 CrossRef
  7. Maus, MK, Mack, PC, Astrow, SH, Stephens, CL, Zeger, GD, Grimminger, PP, Hsiang, JH, Huang, E, Li, T, Lara, PN, Danenberg, KD, Gandara, DR (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8: pp. 582-586
  8. Rosell, R, Danenberg, KD, Alberola, V, Bepler, G, Sanchez, JJ, Camps, C, Provencio, M, Isla, D, Taron, M, Diz, P, Artal, A, Spanish Lung Cancer, G (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: pp. 1318-1325 CrossRef
  9. Rouquette, I, Mazieres, J (2011) A brief overview of a lung cancer biomarker: thymidylate synthase. Rev Mal Respir 28: pp. 773-777 CrossRef
  10. Yokomise, H, Liu, D, Chang, S, Go, T, Ishikawa, S, Misaki, N, Nakashima, N (2013) Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. Anticancer Res 33: pp. 1107-1115
  11. Bergot, E, Levallet, G, Campbell, K, Dubois, F, Lechapt, E, Zalcman, G (2013) Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev 22: pp. 565-576 CrossRef
  12. Passaro, A, Palazzo, A, Trenta, P, Mancini, ML, Morano, F, Cortesi, E (2012) Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. Curr Med Chem 19: pp. 3689-3700 CrossRef
  13. Azuma, K, Komohara, Y, Sasada, T, Terazaki, Y, Ikeda, J, Hoshino, T, Itoh, K, Yamada, A, Aizawa, H (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98: pp. 1336-1343 CrossRef
  14. Olaussen, KA, Dunant, A, Fouret, P, Brambilla, E, Andre, F, Haddad, V, Taranchon, E, Filipits, M, Pirker, R, Popper, HH, Stahel, R, Sabatier, L, Pignon, JP, Tursz, T, Chevalier, T, Soria, JC, Investigators, IB (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: pp. 983-991 CrossRef
  15. Nicolson, MC, Fennell, DA, Ferry, D, O’Byrne, K, Shah, R, Potter, V, S
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

Purpose Recent clinical trials showed that expression of excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and thymidylate synthase (TS) proteins was able to predict the effects of non-small cell lung cancer (NSCLC) to chemotherapy. However, it remains unknown whether the adjuvant chemotherapy based on expression of the three proteins has survival significance in Chinese NSCLC patients. Methods We investigated 128 Chinese patients receiving chemotherapy after tumor resection for expression of these proteins using immunohistochemistry. Based on protein expression, patients were assigned to two groups for different adjuvant chemotherapy regimes. The disease-free survival (DFS) data were collected and analyzed using Kaplan–Meier curves and Cox models. Results We found that DFS of these patients with carboplatin and a third-generation agent (gemcitabine or pemetrexed) stratified by protein expression showed no statistical difference between individual treatment versus non-individuation treatment analyzed using Kaplan–Meier method (P?=?0.143, median 23.9 vs. 30.8?months). Furthermore, the multivariate analysis showed that histology and tumor stages were independent predictors for DFS in these patients. Conclusions The results suggest that chemotherapy based on ERCC1, RRM1, and TS expression did not have significant impact on DFS of patients with resection of NSCLC.